Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept ...
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for ...
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept
Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...
Bladder Full But Can't Pee? What It Means For Men
Small leaks sinks big ships, if any urine issues are addressed at the earlier stage itself, it can prevent future disasters ...
Scientific Research Publishing2 天
Macroscopic hematuria as a presentation of gestational trophoblastic neoplasia in an ...
Three weeks later, she had massive gross hematuria and acute urinary retention. Multiple lesions at right kidney, right ovary and both lungs were identified from emergency ultrasonography and computed ...
Renal & Urology News3 天
Cretostimogene Continues to Show Durable Response in BCG Unresponsive NMIBC
Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.
Pharmabiz2 天
Dr Sanjay Agrawal applies for patent for a specialized formulation for CKD related ...
Dr Sanjay Agrawal applies for patent for a specialized formulation for CKD related nutritional deficiencies: Shardul Nautiyal, Mumbai Wednesday, April 2, 2025, 08:00 Hrs [IST] Dr ...
Le Lézard3 天
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney ...
Travere Therapeutics, Inc., today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring ...